GHRP-2 and GHRP-6 are second-generation synthetic growth hormone releasing peptides with GHSR-1a agonist activity. Comparative pharmacology studies characterise differences in receptor binding affinity, functional potency, and selectivity profiles across pituitary and peripheral cell model systems.

GHRP-2 Research Profile

Molecular Properties

  • Sequence: D-Ala-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2
  • MW: 817.97 g/mol
  • CAS: 158861-67-7

GHRP-2 demonstrates high GHSR-1a binding affinity in competitive radioligand assays. Functional cAMP accumulation studies in CHO cells expressing recombinant GHSR-1a reveal concentration-dependent receptor activation with EC50 values typically ranging 0.1-1.0 nM. Calcium mobilisation assays confirm robust G-protein coupled signalling pathway engagement through Gq/11 mechanisms.

Receptor Binding Kinetics

Saturation binding experiments using [125I]-labeled GHRP-2 demonstrate specific binding to GHSR-1a with Kd values of approximately 0.3-0.8 nM in membrane preparations. Competition studies against ghrelin indicate comparable affinity profiles, though GHRP-2 exhibits enhanced metabolic stability in plasma-containing media.

Functional Selectivity

GHRP-2 displays minimal cross-reactivity with related peptide receptors in selectivity panels. Binding assays against opioid, melanocortin, and neuropeptide Y receptors confirm >1000-fold selectivity for GHSR-1a. This specificity profile supports its utility in targeted receptor pharmacology investigations.

GHRP-6 Research Profile

Molecular Properties

  • Sequence: His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
  • MW: 872.44 g/mol
  • CAS: 87616-84-0

GHRP-6 exhibits potent GHSR-1a agonism with distinct pharmacological characteristics compared to GHRP-2. In vitro binding studies reveal high-affinity interactions with GHSR-1a, though with subtle differences in binding kinetics and downstream signalling efficacy.

Receptor Activation Mechanisms

Functional assays measuring intracellular cAMP levels demonstrate GHRP-6's ability to activate adenylyl cyclase pathways with EC50 values typically in the 0.5-2.0 nM range. Real-time calcium imaging experiments confirm rapid Ca2+ mobilisation upon receptor engagement, indicating efficient G-protein coupling.

Metabolic Stability Profile

Enzyme stability assays reveal GHRP-6's susceptibility to peptidase degradation, particularly at the N-terminal histidine residue. This characteristic influences experimental design considerations in extended incubation protocols and necessitates protease inhibitor inclusion in certain assay conditions.

Comparative Receptor Pharmacology

Binding Affinity Analysis

Direct comparison studies using identical membrane preparations demonstrate subtle differences in GHSR-1a binding affinity between GHRP-2 and GHRP-6. Scatchard analysis reveals GHRP-2 typically exhibits 2-3 fold higher binding affinity, though both peptides achieve complete receptor occupancy at saturating concentrations.

Functional Potency Differences

Concentration-response curves in multiple cell line models reveal distinct potency profiles. GHRP-2 consistently demonstrates enhanced functional potency in cAMP accumulation assays, with leftward shifts in EC50 values compared to GHRP-6. These differences likely reflect variations in receptor-ligand interaction kinetics and downstream signalling efficiency.

Signalling Pathway Selectivity

Both peptides activate primary GHSR-1a signalling cascades through Gq/11-mediated pathways. However, pathway analysis reveals subtle differences in secondary messenger profiles. GHRP-2 shows more pronounced IP3/DAG pathway activation, while GHRP-6 demonstrates enhanced calcium-dependent protein kinase C activation patterns.

Cell Model Applications

Primary Culture Systems

Pituitary adenoma cell lines provide relevant models for comparative pharmacology studies. Both GHRP-2 and GHRP-6 demonstrate concentration-dependent responses in these systems, though with distinct temporal profiles and maximum response amplitudes.

Recombinant Expression Models

HEK293 and CHO cell lines stably expressing GHSR-1a offer standardised platforms for mechanistic studies. These systems enable precise characterisation of receptor binding kinetics, G-protein coupling efficiency, and downstream effector activation patterns.

Research Summary

Comparative pharmacological analysis reveals GHRP-2 and GHRP-6 as potent GHSR-1a agonists with distinct receptor interaction profiles. GHRP-2 demonstrates superior binding affinity and functional potency, while GHRP-6 exhibits unique signalling pathway preferences. Both peptides maintain excellent receptor selectivity, making them valuable tools for in vitro GHSR-1a pharmacology research. The observed differences in binding kinetics, functional potency, and metabolic stability inform experimental design considerations for specific research applications requiring precise GHSR-1a modulation.

All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.